Relieves interstitial cystitis. Sold as Rimso-50. Every FDA application for this active ingredient: 1 branded and 2 generic.
As of Nov 15, 2026, FDA lists 3 applications for Dimethyl Sulfoxide (sold as Rimso-50), first approved Apr 4, 1978, with 0 new uses approved and 0 published complete response letters.
| Rimso-50 | Part B | $3.9M | +5% | 728 |
| Rimso-50 | Part D | $572K | +1% | 95 |
| Comparing MOP, Prostaglandin E1, and Calcitriol to Accelerate Orthodontic Tooth MovementAccelerated Orthodontic Tooth Movement · Ghufran Dhari Awad | Phase 2 | Recruiting | Sep 25, 2026 |
| DMSO Dual-Route Therapy for Refractory Tinnitus in Long-COVID and Post-COVID-19 Vaccine InjuryTinnitus · Leading Edge Clinic | Phase 2 | Enrolling by invitation | May 5, 2026 |
| Effect of Local Use of Vitamin D on the Rate of Canine Distillization: a Split Mouth Randomized Control TrialMalocclusion of Anterior Teeth · Foundation University Islamabad | Phase 1 | Recruiting | Mar 18, 2026 |
| Evaluation of In-Vitro Cryo Therapeutic Protocols on Human Cell Samples (TWH-CRYO-001)Cellular Injury and Post-Cryogenic Recovery, Cryogenic Cellular Stress · Truway Health, Inc. | Early phase 1 | Enrolling by invitation | Jan 6, 2026 |
| Efficacy of Prostatic Arteries Embolization Using SQUIDPERIBenign Prostate Hypertrophy(BPH) · Assistance Publique - Hôpitaux de Paris | — | Not yet recruiting | Dec 1, 2025 |
| Dabrafenib and Trametinib for BRAF V600 Mutant Low-Grade GliomasBRAF V600 Mutation, Low-grade Glioma · University of California, San Francisco | Phase 2 | Recruiting | Aug 7, 2025 |
| Stop Air Leak by Talc or Autologous Blood Patch TherapyPneumothorax Spontaneous Secondary · Chinese University of Hong Kong | Phase 2 / Phase 3 | Not yet recruiting | Mar 19, 2025 |
| The Effect of Topical Imipramine on Photodynamic Therapy-Mediated Immunosuppression on Forearms or Face on US VeteransActinic Keratosis, Imipramine · VA Office of Research and Development | Phase 2 | Recruiting | Jan 16, 2025 |
| Apr 4, 1978 | Rimso-50NDA 17788 · New molecular entity | Mylan Institutional | 11 | Marketed |
| Nov 29, 2002 | Dimethyl SulfoxideANDA 76185 | Mylan Institutional | 0 | Discontinued |
| Jul 7, 2026 | Dimethyl SulfoxideANDA 220173 | Pharmobedient | 0 | Marketed |
Applications, approvals and products come from FDA's Drugs@FDA data files, refreshed weekly, grouped by active ingredient as FDA spells it. Complete response letters are FDA's published letters. Medicare spending is CMS's Part D and Part B dashboard, matched to this ingredient by generic name; shortages are FDA's shortage list, matched by application number; clinical trials are ClinicalTrials.gov studies naming the ingredient as an intervention, refreshed daily; safety programs are FDA's REMS list, matched by application number or, for shared programs, by ingredient. Drugs@FDA
